TABLE 1.
Clinical and laboratory characteristics of the patients
| Characteristics |
All (N = 152) |
PVS+ (N = 41) |
PVS− (N = 111) |
p Value |
|---|---|---|---|---|
| Age (years) | 60.37 ± 10.1 | 61.73 ± 9.1 | 59.85 ± 10.4 | .308 |
| Male gender (%) | 89.47 (136) | 97.56 (40) | 86.49 (96) | .048 |
| Diabetes mellitus (%) | 21.3 (32) | 36.6 (15) | 15.6 (17) | .005 |
| Hypertension (%) | 58 (87) | 63.4 (26) | 56 (61) | .410 |
| Dyslipidemia (%) | 66 (99) | 68.3 (28) | 65.1 (71) | .716 |
| Smoking (%) | 52.7 (79) | 53.7 (22) | 52.3 (57) | .881 |
| Hereditary SCD (%) | 4.7 (7) | 4.9 (2) | 4.6 (5) | .940 |
| Hereditary CAD (%) | 22.5 (34) | 36.6 (15) | 17.3 (19) | .012 |
| BMI (kg/m2) | 27.7 ± 4.2 | 27.25 ± 3.5 | 28.15 ± 4.9 | .213 |
| b‐Blockers (% yes) | 91 (137) | 90.24 (37) | 91 (100) | .900 |
| ACE or ARBs (% yes) | 72.85 (110) | 80.5 (33) | 70 (77) | .197 |
| Aspirin (% yes) | 96.7 (146) | 95.1 (39) | 97.3 (107) | .511 |
| P2Y12 inhibitors (% yes) | 86.8 (131) | 80.5 (33) | 89.1 (98) | .165 |
| Statin (% yes) | 95.4 (144) | 100 (41) | 93.6 (103) | .098 |
| Diuretics (% yes) | 17.9 (27) | 29.3 (12) | 13.6 (15) | .026 |
| CCBs (% yes) | 14.1 (21) | 14.6 (6) | 13.9 (15) | .907 |
| MRAs (% yes) | 13.3 (20) | 29.3 (12) | 7.3 (8) | .001 |
| LVEF (%) | 49.6 ± 7 | 45.6 ± 4.9 | 51.1 ± 7.1 | .001 |
| LVEDD (mm) | 51.4 ± 6 | 53.25 ± 6.3 | 50.7 ± 5.7 | .021 |
| STEMI (%) | 62 (93) | 82.9 (34) | 54.1 (59) | .001 |
| One‐VD (% yes) | 60.7 (91) | 53.7 (22) | 63.3 (69) | .478 |
| LAD (% yes) | 56.7 (85) | 58.5 (24) | 56 (61) | .777 |
| LCx (% yes) | 46.7 (70) | 46.3 (19) | 46.8 (51) | .961 |
| RCA (% yes) | 54 (81) | 63.4 (26) | 50.5 (55) | .156 |
| AECG characteristics | ||||
| QRS (ms) | 93.66 ± 20.74 | 92.94 ± 22.6 | 93.92 ± 20.1 | .812 |
| f‐QRS (ms) | 106.66 ± 20.86 | 115.35 ± 23.5 | 103.7 ± 19.1 | .045 |
| LAS (ms) | 61.13 ± 269.99 | 67.13 ± 312.5 | 43.47 ± 19.8 | .072 |
| RMS 40 (μV) | 34.76 ± 27.24 | 26.27 ± 23.8 | 37.64 ± 27.8 | .013 |
| NSVT (total No) | 0.89 ± 3.69 | 1.73 ± 4.98 | 0.56 ± 3.01 | .003 |
| PVCs (total No) | 2126.34 ± 4923.68 | 1583.9 ± 4288.4 | 2329.8 ± 5146.3 | .628 |
| SDNN (ms) | 123.25 ± 44.82 | 117.42 ± 40.8 | 125.35 ± 40.2 | .376 |
| QTc (ms) | 463.15 ± 24.30 | 438.92 ± 22.96 | 435.12 ± 24.82 | .552 |
| DC (ms) | 2.50 ± 9.59 | 2.15 ± 11 | 2.63 ± 9.1 | .799 |
| HRTo (%) | −0.01 ± 0.02 | −0.01 ± 0.02 | −0.02 ± 0.03 | .544 |
| HRTs (ms) | 6.96 ± 5.36 | 6.79 ± 4.59 | 7.02 ± 5.67 | .832 |
| TWA ≥65 μV (%) | 21.5 (32) | 24.4 (10) | 20.4 (22) | .594 |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blockers; BMI, body mass index; CCBs, calcium channel blockers; DC, deceleration capacity; fQRS, filtered QRS; HRTo, heart rate turbulence onset; HRTs, heart rate turbulence slope; LAD, left anterior descending artery; LAS, low amplitude (<40 µV) signal duration; LCX, circumflex artery; LPS, late potentials; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor antagonists; NSVT, non‐sustained ventricular tachycardia; One‐VD, one vessel disease; PVCs, premature ventricular complexes; QTc, corrected QT interval; RCA, right coronary artery; RMS, terminal (last 40 ms) QRS root means square voltage; SDNN, standard deviation of normal to normal heartbeat; STEMI, ST‐segment elevation myocardial infarction; TWA, T‐wave alternans.